- Home
- COCP vs AKTX Comparison
COCP vs AKTX Comparison
Compare COCP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCP
- AKTX
- Stock Information
- Founded
- COCP 2006
- AKTX N/A
- Country
- COCP United States
- AKTX United States
- Employees
- COCP N/A
- AKTX N/A
- Industry
- COCP Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- COCP Health Care
- AKTX Health Care
- Exchange
- COCP Nasdaq
- AKTX Nasdaq
- Market Cap
- COCP 15.4M
- AKTX 17.2M
- IPO Year
- COCP N/A
- AKTX N/A
- Fundamental
- Price
- COCP $1.00
- AKTX $0.47
- Analyst Decision
- COCP Strong Buy
- AKTX Strong Buy
- Analyst Count
- COCP 1
- AKTX 2
- Target Price
- COCP $6.00
- AKTX $3.30
- AVG Volume (30 Days)
- COCP 82.9K
- AKTX 472.5K
- Earning Date
- COCP 11-14-2025
- AKTX 11-13-2025
- Dividend Yield
- COCP N/A
- AKTX N/A
- EPS Growth
- COCP N/A
- AKTX N/A
- EPS
- COCP N/A
- AKTX N/A
- Revenue
- COCP N/A
- AKTX N/A
- Revenue This Year
- COCP N/A
- AKTX N/A
- Revenue Next Year
- COCP N/A
- AKTX N/A
- P/E Ratio
- COCP N/A
- AKTX N/A
- Revenue Growth
- COCP N/A
- AKTX N/A
- 52 Week Low
- COCP $0.90
- AKTX $0.42
- 52 Week High
- COCP $3.26
- AKTX $1.73
- Technical
- Relative Strength Index (RSI)
- COCP 46.82
- AKTX 34.84
- Support Level
- COCP $0.90
- AKTX $0.42
- Resistance Level
- COCP $0.96
- AKTX $0.55
- Average True Range (ATR)
- COCP 0.05
- AKTX 0.06
- MACD
- COCP 0.00
- AKTX -0.00
- Stochastic Oscillator
- COCP 51.06
- AKTX 24.16
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.